相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Left-Sided Degenerative Valvular Heart Disease in Type 1 and Type 2 Diabetes
Araz Rawshani et al.
CIRCULATION (2022)
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis
Milad Nazarzadeh et al.
LANCET DIABETES & ENDOCRINOLOGY (2022)
Range of Risk Factor Levels, Risk Control, and Temporal Trends for Nephropathy and End-stage Kidney Disease in Patients With Type 1 and Type 2 Diabetes
Janita Halminen et al.
DIABETES CARE (2022)
Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial
Geltrude Mingrone et al.
LANCET (2021)
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study
Susanna C. Larsson et al.
EUROPEAN HEART JOURNAL (2020)
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes? Completed and Ongoing Mechanistic Trials
Matthew M. Y. Lee et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)
Age-, sex- and ethnicity-related differences in body weight, blood pressure, HbA1c and lipid levels at the diagnosis of type 2 diabetes relative to people without diabetes
Alison K. Wright et al.
DIABETOLOGIA (2020)
Mechanisms of Sodium-Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics
Ele Ferrannini et al.
DIABETES CARE (2020)
Understanding the mechanisms of reversal of type 2 diabetes
Roy Taylor et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Heart Failure in Type 2 Diabetes Mellitus Impact of Glucose-Lowering Agents, Heart Failure Therapies, and Novel Therapeutic Strategies
Helena C. Kenny et al.
CIRCULATION RESEARCH (2019)
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
Michael E. J. Lean et al.
LANCET (2018)
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Aidin Rawshani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prescriber Patterns of SGLT2i After Expansions of US Food and Drug Administration Labeling
Muthiah Vaduganathan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
Aidin Rawshani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effect of Multifactorial Treatment Targets and Relative Importance of Hemoglobin A1c, Blood Pressure, and Low-Density LipoproteinCholesterol on Cardiovascular Diseases in Chinese Primary Care Patients With Type 2 Diabetes Mellitus: A Population-Based Retrospective Cohort Study
Eric Yuk Fai Wan et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Range of Risk Factor Levels Control, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes Mellitus
Aidin Rawshani et al.
CIRCULATION (2017)
Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial
Peter Gde et al.
DIABETOLOGIA (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
Faramarz Ismail-Beigi et al.
LANCET (2010)
Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis
LANCET (2008)
Long-term follow-up after tight control of blood pressure in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
HM Colhoun et al.
LANCET (2004)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
分享论文
